Posted in | News | Uranium

Macusani Yellowcake Proclaims Additional Assay Results from Kihitian Property

Macusani Yellowcake has released further drilling results from the Chilcuno Chico region at the Kihitian Property in Peru. These drilling results sustain the expansion of the deeper Manto B zone.

The company has intersected 1,020 ppm U3O8 over 37 m including 11,996 ppm U3O8 over 3.0 m at the high-grade zone. These assay results belong to the 14 and 17 platforms at the Kihitian’s Chilcuno Chico region.

The location of the platform 17 is 120 m to the adits’ North-West part, which was unearthed during the 1980’s by IPEN, whereas platform 14 was sited 400 m to the adits’ South-West part. The company has drilled the borehole CH17-SW adjacent to the access road that leads to the drilling region, at a lower altitude zone where the Manto A zone was entirely eroded and Manto B lies nearer to the surface. The location of the borehole CH14-V is over the current operations in the Chilcuno Chico mountain, which is the region where both A and B mineralized levels were conserved theoretically. These two platforms are situated 350 m away in a SW-NE direction.

The company has cut 0.0209% U3O8 over 2 m in the vertical hole CH14-V at the platform 14 in the level A mineralization, 0.0402% U3O8 over 24 m and 0.111% U3O8 over 8 m in the borehole CH17-SW at level B mineralization.

Macusani has drilled the vertical bore hole CH14-V and an inclined bore hole CH17-SW at 55° towards Southwest.

The CEO of the company has commented that the complete drilling activities have started again at the Kihitian uranium property and show the high-grade uranium intercepts continuously in the Chilcuno region. Macusani plans to carry on its drilling program at the Macusani during the winter season.

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 18). Macusani Yellowcake Proclaims Additional Assay Results from Kihitian Property. AZoMining. Retrieved on June 23, 2024 from

  • MLA

    Scanlon, Joel. "Macusani Yellowcake Proclaims Additional Assay Results from Kihitian Property". AZoMining. 23 June 2024. <>.

  • Chicago

    Scanlon, Joel. "Macusani Yellowcake Proclaims Additional Assay Results from Kihitian Property". AZoMining. (accessed June 23, 2024).

  • Harvard

    Scanlon, Joel. 2019. Macusani Yellowcake Proclaims Additional Assay Results from Kihitian Property. AZoMining, viewed 23 June 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.